Incorporating biomarkers into clinical trials in cardiovascular medicine

References

• Murphy SL, Xu J, Kochanek KD. Deaths: Final Data for 2010. National Vital Statistics Reports; 2013. Available from: http://www.cdc.gov/nchs/data/nvsr/nvsr61/nvsr61_04.pdf. Accessed February, 1 2014.
   Google Scholar
• Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89–95.
   PubMed Web of Science ®Google Scholar
• Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation. 2006;113(19):2335–2362.
   PubMed Web of Science ®Google Scholar
• Vogel CL, Cobleigh MA, Tripathy D, et al. First-line Herceptin monotherapy in metastatic breast cancer. Oncology. 2001;61 Suppl 2:37–42.
   Google Scholar
• Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–1847.
   PubMed Web of Science ®Google Scholar
• Straus SM1, Kors JA, De Bruin ML, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol. 2006;47(2):362–367.
   PubMed Web of Science ®Google Scholar
• Yousuf O1, Mohanty BD, Martin SS, et al. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link? J Am Coll Cardiol. 2013;62(5):397–408.
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–3421.
   Web of Science ®Google Scholar
• Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1998;98(9):839–844.
   PubMed Web of Science ®Google Scholar
• Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. JAMA.1982;248:465–1477.
   Google Scholar
• Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98(8):731–733.
   PubMed Web of Science ®Google Scholar
• Blaha MJ1, Rivera JJ, Budoff MJ, et al. Association between obesity, high-sensitivity C-reactive protein >/=2 mg/L, and subclinical atherosclerosis: implications of JUPITER from the Multi-Ethnic Study of Atherosclerosis. Arterioscler Thromb Vasc Biol. 2011;31(6):1430–1438.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207.
   PubMed Web of Science ®Google Scholar
• Hingorani AD1, Sofat R, Morris RW, et al. Is it important to measure or reduce C-reactive protein in people at risk of cardiovascular disease? Eur Heart J. 2012;33(18):2258–2264.
   Web of Science ®Google Scholar
• Sattar N, Murray HM, McConnachie A, et al; PROSPER Study Group. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation. 2007;115(8):981–989.
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group, Jonathan Emberson, Derrick Bennett, et al. C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study. Lancet. 2011;377(9764):469–476.
   Web of Science ®Google Scholar
• Woloshin S, Schwartz LM. Distribution of C-reactive protein values in the United States. N Engl J Med. 2005;352(15):1611–1613.
   PubMed Web of Science ®Google Scholar
• Harris TB, Ferrucci L, Tracy RP, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med. 1999;106(5):506–512.
   PubMed Web of Science ®Google Scholar
• Gupta NK, de Lemos JA, Ayers CR, Abdullah SM, McGuire DK, Khera A. The relationship between C-reactive protein and atherosclerosis differs on the basis of body mass index: the Dallas Heart Study. J Am Coll Cardiol. 2012;60(13):1148–1155.
   Web of Science ®Google Scholar
• Bower JK, Lazo M, Juraschek SP, Selvin E. Within-person variability in high-sensitivity C-reactive protein. Arch Intern Med. 2012;172(19):1519–1521.
   Google Scholar
• Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation. 2002;106(3):388–391.
   PubMed Web of Science ®Google Scholar
• Farnier M. PCSK9: From discovery to therapeutic applications. Arch Cardiovasc Dis. 2014;107(1):58–66.
   PubMed Web of Science ®Google Scholar
• Lose JM, Dorsch MP, Bleske BE. Evaluation of proprotein convertase subtilisin/kexin type 9: focus on potential clinical and therapeutic implications for low-density lipoprotein cholesterol lowering. Pharmacotherapy. 2013;33(4):447–460.
   Web of Science ®Google Scholar
• Folsom AR, Peacock JM, Boerwinkle E. Variation in PCSK9, low LDL cholesterol, and risk of peripheral arterial disease. Atherosclerosis. 2009;202(1):211–215.
   Web of Science ®Google Scholar
• Hallman DM, Srinivasan SR, Chen W, Boerwinkle E, Berenson GS. Relation of PCSK9 mutations to serum low-density lipoprotein cholesterol in childhood and adulthood (from The Bogalusa Heart Study). Am J Cardiol. 2007;100(1):69–72.
   Web of Science ®Google Scholar
• Careskey HE, Davis RA, Alborn WE, Troutt JS, Cao G, Konrad RJ. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res. 2008;49(2):394–398.
   PubMed Web of Science ®Google Scholar
• Awan Z, Seidah NG, MacFadyen JG, et al. Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial. Clin Chem. 2012;58(1):183–189.
   Web of Science ®Google Scholar
• Blann AD, Nadar SK, Lip GY. The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J. 2003;24(24):2166–2179.
   PubMed Web of Science ®Google Scholar
• Nijmeijer R1, Meuwissen M, Krijnen PA, et al. Secretory type II phospholipase A2 in culprit coronary lesions is associated with myocardial infarction. Eur J Clin Invest. 2008;38(4):205–210.
   Web of Science ®Google Scholar
• Blann AD1, Lip GY. Hypothesis: is soluble P-selectin a new marker of platelet activation? Atherosclerosis. 1997;128(2):135–138.
   PubMed Web of Science ®Google Scholar
• Woollard KJ1, Kling D, Kulkarni S, Dart AM, Jackson S, Chin-Dusting J. Raised plasma soluble P-selectin in peripheral arterial occlusive disease enhances leukocyte adhesion. Circ Res. 2006;98(1):149–156.
   Web of Science ®Google Scholar
• Galkina E, Ley K. Double jeopardy: how soluble P-selectin activates leukocytes in peripheral arterial occlusive disease. Circ Res. 2006;98(1):12–14.
   Web of Science ®Google Scholar
• Myers DD1, Hawley AE, Farris DM, et al. P-selectin and leukocyte microparticles are associated with venous thrombogenesis. J Vasc Surg. 2003;38(5):1075–1089.
   Web of Science ®Google Scholar
• André P, Hartwell D, Hrachovinová I, Saffaripour S, Wagner DD. Pro-coagulant state resulting from high levels of soluble P-selectin in blood. Proc Natl Acad Sci U S A. 2000;97(25):13835–13840.
   PubMed Web of Science ®Google Scholar
• Blann A1, Morris J, McCollum C. Soluble L-selectin in peripheral arterial disease: relationship with soluble E-selectin and soluble P-selectin. Atherosclerosis. 1996;126(2):227–231.
   Web of Science ®Google Scholar
• Davì G, Romano M, Mezzetti A, et al. Increased levels of soluble P-selectin in hypercholesterolemic patients. Circulation. 1998;97(10):953–957.
   PubMed Web of Science ®Google Scholar
• Lip GY1, Blann AD, Zarifis J, Beevers M, Lip PL, Beevers DG. Soluble adhesion molecule P-selectin and endothelial dysfunction in essential hypertension: implications for atherogenesis? A preliminary report. J Hypertens. 1995;13(12 Pt 2):1674–1678.
   Web of Science ®Google Scholar
• Ikeda H1, Takajo Y, Ichiki K, et al. Increased soluble form of P-selectin in patients with unstable angina. Circulation. 1995;92(7):1693–1696.
   Web of Science ®Google Scholar
• Kisucka J, Chauhan AK, Zhao BQ, et al. Elevated levels of soluble P-selectin in mice alter blood-brain barrier function, exacerbate stroke, and promote atherosclerosis. Blood. 2009;113(23):6015–6022.
   Web of Science ®Google Scholar
• Badr Eslam R, Gremmel T, Schneller A, et al. High levels of platelet-monocyte aggregates after valve replacement for aortic stenosis: relation to soluble P-selectin and P-selectin glycoprotein ligand-1 genes. Thromb Res. 2012;129(4):453–458.
   Web of Science ®Google Scholar
• van Gils JM1, Zwaginga JJ, Hordijk PL. Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases. J Leukoc Biol. 2009;85(2):195–204.
   Web of Science ®Google Scholar
• Myers DD Jr, Schaub R, Wrobleski SK, et al. P-selectin antagonism causes dose-dependent venous thrombosis inhibition. Thromb Haemost. 2001;85(3):423–429.
   PubMed Web of Science ®Google Scholar
• Oostingh GJ, Pozgajova M, Ludwig RJ, et al. Diminished thrombus formation and alleviation of myocardial infarction and reperfusion injury through antibody- or small-molecule-mediated inhibition of selectin-dependent platelet functions. Haematologica. 2007;92(4):502–512.
   Web of Science ®Google Scholar
• Sim D1, Flaumenhaft R, Furie B, Furie B. Interactions of platelets, blood-borne tissue factor, and fibrin during arteriolar thrombus formation in vivo. Microcirculation. 2005;12(3):301–311.
   Web of Science ®Google Scholar
• Wang J1, Zhang S, Jin Y, Qin G, Yu L, Zhang J. Elevated levels of platelet-monocyte aggregates and related circulating biomarkers in patients with acute coronary syndrome. Int J Cardiol. 2007;115(3):361–365.
   Web of Science ®Google Scholar
• Freedman JE, Loscalzo J. Platelet-monocyte aggregates: bridging thrombosis and inflammation. Circulation. 2002;105(18):2130–2132.
   Web of Science ®Google Scholar
• Kling D, Stucki C, Kronenberg S, et al. Pharmacological control of platelet-leukocyte interactions by the human anti-P-selectin antibody inclacumab – preclinical and clinical studies. Thromb Res. 2013;131(5):401–410.
   Web of Science ®Google Scholar
• Liuzzo G. Atherosclerosis: an inflammatory disease. Rays. 2001;26(4):221–230.
   Google Scholar
• Weissberg PL, Bennett MR. Atherosclerosis – an inflammatory disease. N Engl J Med. 1999;340(24):1928–1929.
   PubMed Web of Science ®Google Scholar
• Williams KJ, Tabas I. Atherosclerosis – an inflammatory disease. N Engl J Med. 1999;340(24):1928; author reply 1929.
   Google Scholar
• Sloop GD. Atherosclerosis – an inflammatory disease. N Engl J Med. 1999;340(24):1928; author reply 1929.
   Google Scholar
• Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med. 1999;340(2):115–126.
   PubMed Web of Science ®Google Scholar
• Marecková Z, Heller S, Horký K. [Cell adhesion molecules and their role in pathophysiologic processes]. Vnitr Lek. 1999;45(1):46–50. Czech.
   Google Scholar
• Golias C, Tsoutsi E, Matziridis A, Makridis P, Batistatou A, Charalabopoulos K. Review. Leukocyte and endothelial cell adhesion molecules in inflammation focusing on inflammatory heart disease. In Vivo. 2007;21(5):757–769.
   PubMed Web of Science ®Google Scholar
• Alfonso F, Angiolillo DJ. Targeting p-selectin during coronary interventions: the elusive link between inflammation and platelets to prevent myocardial damage. J Am Coll Cardiol. 2013;61(20):2056–2059.
   Web of Science ®Google Scholar
• Cambien B, Wagner DD. A new role in hemostasis for the adhesion receptor P-selectin. Trends Mol Med. 2004;10(4):179–186.
   Web of Science ®Google Scholar
• Johnson-Tidey RR, McGregor JL, Taylor PR, Poston RN. Increase in the adhesion molecule P-selectin in endothelium overlying atherosclerotic plaques. Coexpression with intercellular adhesion molecule-1. Am J Pathol. 1994;144(5):952–961.
   Web of Science ®Google Scholar
• Cassar K1, Bachoo P, Ford I, Greaves M, Brittenden J. Platelet activation is increased in peripheral arterial disease. J Vasc Surg. 2003;38(1):99–103.
   Web of Science ®Google Scholar
• Zeiger F, Stephan S, Hoheisel G, Pfeiffer D, Ruehlmann C, Koksch M. P-Selectin expression, platelet aggregates, and platelet-derived microparticle formation are increased in peripheral arterial disease. Blood Coagul Fibrinolysis. 2000;11(8):723–728.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Kereiakes DJ, Dalesandro MR, Bahr RD, O’Connor CM, Serebruany VL. Role of soluble and platelet-bound P-selectin in discriminating cardiac from noncardiac chest pain at presentation in the emergency department. Am Heart J. 2000;139(2 Pt 1):320–328.
   Web of Science ®Google Scholar
• Tenaglia AN1, Buda AJ, Wilkins RG, et al. Levels of expression of P-selectin, E-selectin, and intercellular adhesion molecule-1 in coronary atherectomy specimens from patients with stable and unstable angina pectoris. Am J Cardiol. 1997;79(6):742–747.
   Web of Science ®Google Scholar
• Stellos K, Bigalke B, Stakos D, Henkelmann N, Gawaz M. Platelet-bound P-selectin expression in patients with coronary artery disease: impact on clinical presentation and myocardial necrosis, and effect of diabetes mellitus and anti-platelet medication. J Thromb Haemost. 2010;8(1):205–207.
   Web of Science ®Google Scholar
• Cao YJ1, Wang YM, Zhang J, Zeng YJ, Liu CF. The effects of antiplatelet agents on platelet-leukocyte aggregations in patients with acute cerebral infarction. J Thromb Thrombolysis. 2009;27(2):233–238.
   Web of Science ®Google Scholar
• Nadar SK, Lip GY, Blann AD. Platelet morphology, soluble P selectin and platelet P-selectin in acute ischaemic stroke. The West Birmingham Stroke Project. Thromb Haemost. 2004;92(6):1342–1348.
   PubMed Web of Science ®Google Scholar
• Yusuf SW, Sanderson H, Heptinstall S, Nurden AT, Wenham PW, Hopkinson BR. ADP-induced P-selectin expression on platelets as a predictor of successful thrombolysis. Blood Coagul Fibrinolysis. 1996;7(2):266–269.
   Web of Science ®Google Scholar
• Kayikçioglu M, Can L, Mete-Erdem N, et al. Soluble P-selectin and the success of thrombolysis in acute myocardial infarction. Int J Cardiol. 2001;79(2–3):223–229.
   Web of Science ®Google Scholar
• Minamino T, Kitakaze M, Asanuma H, et al. Plasma adenosine levels and platelet activation in patients with atrial fibrillation. Am J Cardiol. 1999;83(2):194–198.
   PubMed Web of Science ®Google Scholar
• Shimomura H1, Ogawa H, Arai H, et al. Serial changes in plasma levels of soluble P-selectin in patients with acute myocardial infarction. Am J Cardiol. 1998;81(4):397–400.
   Web of Science ®Google Scholar
• Thomas R, Cheng Y, Yan J, et al. Upregulation of coronary endothelial P-selectin in a monkey heart ischemia reperfusion model. J Mol Histol. 2010;41(4–5):277–287.
   Web of Science ®Google Scholar
• Hansen A1, Kumar A, Wolf D, et al. Evaluation of cardioprotective effects of recombinant soluble P-selectin glycoprotein ligand-immunoglobulin in myocardial ischemia-reperfusion injury by real-time myocardial contrast echocardiography. J Am Coll Cardiol. 2004;44(4):887–891.
   Web of Science ®Google Scholar
• Wang K, Zhou X, Zhou Z, et al. Recombinant soluble P-selectin glycoprotein ligand-Ig (rPSGL-Ig) attenuates infarct size and myeloperoxidase activity in a canine model of ischemia-reperfusion. Thromb Haemost. 2002;88(1):149–154.
   Web of Science ®Google Scholar
• Hayward R, Campbell B, Shin YK, Scalia R, Lefer AM. Recombinant soluble P-selectin glycoprotein ligand-1 protects against myocardial ischemic reperfusion injury in cats. Cardiovasc Res. 1999;41(1):65–76.
   Web of Science ®Google Scholar
• Downing LJ, Wakefield TW, Strieter RM, et al. Anti-P-selectin antibody decreases inflammation and thrombus formation in venous thrombosis. J Vasc Surg. 1997;25(5):816–827; discussion 828.
   Web of Science ®Google Scholar
• Wakefield TW, Strieter RM, Prince MR, Downing LJ, Greenfield LJ. Pathogenesis of venous thrombosis: a new insight. Cardiovasc Surg. 1997;5(1):6–15.
   Google Scholar
• Wakefield TW, Strieter RM, Downing LJ, et al. P-selectin and TNF inhibition reduce venous thrombosis inflammation. J Surg Res. 1996;64(1):26–31.
   Web of Science ®Google Scholar
• Chen LY1, Nichols WW, Hendricks JB, Yang BC, Mehta JL. Monoclonal antibody to P-selectin (PB1.3) protects against myocardial reperfusion injury in the dog. Cardiovasc Res. 1994;28(9):1414–1422.
   Web of Science ®Google Scholar
• Bienvenu JG, Tanguay JF, Théorêt JF, Kumar A, Schaub RG, Merhi Y. Recombinant soluble p-selectin glycoprotein ligand-1-Ig reduces restenosis through inhibition of platelet-neutrophil adhesion after double angioplasty in swine. Circulation. 2001;103(8):1128–1134.
   Web of Science ®Google Scholar
• Kaufmann J, Wellnhofer E, Kappert K, et al. Soluble P-selectin level correlates with acetylsalicylic acid but not with clopidogrel response in patients with stable coronary artery disease after a percutaneous coronary intervention. Coron Artery Dis. 2013;24(4):312–320.
   PubMed Web of Science ®Google Scholar
• Day JR1, Malik IS, Weerasinghe A, et al. Distinct yet complementary mechanisms of heparin and glycoprotein IIb/IIIa inhibitors on platelet activation and aggregation: implications for restenosis during percutaneous coronary intervention. Heart. 2004;90(7):794–799.
   Web of Science ®Google Scholar
• Koenig A, Norgard-Sumnicht K, Linhardt R, Varki A. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest. 1998;101(4):877–889.
   PubMed Web of Science ®Google Scholar
• Xie X, Rivier AS, Zakrzewicz A, et al. Inhibition of selectin-mediated cell adhesion and prevention of acute inflammation by nonanticoagulant sulfated saccharides. Studies with carboxyl-reduced and sulfated heparin and with trestatin a sulfate. J Biol Chem. 2000;275(44):34818–34825.
   Web of Science ®Google Scholar
• Cha JK, Jeong MH, Kim JW. Statin reduces the platelet P-selectin expression in atherosclerotic ischemic stroke. J Thromb Thrombolysis. 2004;18(1):39–42.
   Web of Science ®Google Scholar
• Marschang P, Friedrich GJ, Ditlbacher H, et al. Reduction of soluble P-selectin by statins is inversely correlated with the progression of coronary artery disease. Int J Cardiol. 2006;106(2):183–190.
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Hurt-Camejo E. Phospholipase A2 enzymes and the risk of atherosclerosis. Eur Heart J. 2012;33(23):2899–2909.
   PubMed Web of Science ®Google Scholar
• Oörni K, Kovanen PT. Lipoprotein modification by secretory phospholipase A(2) enzymes contributes to the initiation and progression of atherosclerosis. Curr Opin Lipidol. 2009;20(5):421–427.
   Web of Science ®Google Scholar
• Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol. 2005;25(5):923–931.
   PubMed Web of Science ®Google Scholar
• Stafforini DM, McIntyre TM, Carter ME, Prescott SM. Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor. J Biol Chem. 1987;262(9):4215–4222.
   Web of Science ®Google Scholar
• Tellis CC, Tselepis AD. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim Biophys Acta. 2009;1791(5):327–338.
   PubMed Web of Science ®Google Scholar
• De Keyzer D, Karabina SA, Wei W, et al. Increased PAFAH and oxidized lipids are associated with inflammation and atherosclerosis in hypercholesterolemic pigs. Arterioscler Thromb Vasc Biol. 2009;29(12):2041–2046.
   PubMed Web of Science ®Google Scholar
• Packard CJ, O’Reilly DS, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med. 2000;343(16):1148–1155.
   PubMed Web of Science ®Google Scholar
• Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J. 2005;26(2):137–144.
   Web of Science ®Google Scholar
• Koenig W, Twardella D, Brenner H, Rothenbacher D. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol. 2006;26(7):1586–1593.
   PubMed Web of Science ®Google Scholar
• Corsetti JP, Rainwater DL, Moss AJ, Zareba W, Sparks CE. High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients. Clin Chem. 2006;52(7):1331–1338.
   Web of Science ®Google Scholar
• Zheng D, Zeng F, Cai A, et al. Baseline elevated Lp-PLA2 is associated with increased risk for re-stenosis after stent placement. Lipids Health Dis. 2014;13:41.
   Web of Science ®Google Scholar
• Möckel M, Müller R, Vollert J, et al. Lipoprotein-associated phospholipase A2 for early risk stratification in patients with suspected acute coronary syndrome: a multi-marker approach: the North Wuerttemberg and Berlin Infarction Study-II (NOBIS-II). Clin Res Cardiol. 2007;96(9):604–612.
   Web of Science ®Google Scholar
• Gerber Y, McConnell JP, Jaffe AS, Weston SA, Killian JM, Roger VL. Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community. Arterioscler Thromb Vasc Biol. 2006;26(11):2517–2522.
   Web of Science ®Google Scholar
• Oldgren J, James SK, Siegbahn A, Wallentin L. Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients. Eur Heart J. 2007;28(6):699–704.
   Web of Science ®Google Scholar
• O’Donoghue M, Morrow DA, Sabatine MS, et al. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation. 2006;113(14):1745–1752.
   Web of Science ®Google Scholar
• STABILITY Investigators, White HD, Held C, et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med. 2014;370(18):1702–1711.
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. GSK announces phase III study with darapladib did not meet primary endpoint in patients following an acute coronary syndrome [press release]. Brentford: GlaxoSmithKline; May 13, 2014. Available from: http://www.gsk.com/media/press-releases/2014/gsk-announces-phase-iii-study-with-darapladib-did-not-meet-prima.html. Accessed May 20, 2014.
   Google Scholar
• Ivandic B, Castellani LW, Wang XP, et al. Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2. Arterioscler Thromb Vasc Biol. 1999;19(5):1284–1290.
   Web of Science ®Google Scholar
• Mallat Z, Benessiano J, Simon T, et al. Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study. Arterioscler Thromb Vasc Biol. 2007;27(5):1177–1183.
   Web of Science ®Google Scholar
• Boekholdt SM, Keller TT, Wareham NJ, et al. Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. Arterioscler Thromb Vasc Biol. 2005;25(4):839–846.
   Web of Science ®Google Scholar
• Kugiyama K, Ota Y, Takazoe K, et al. Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease. Circulation. 1999;100(12):1280–1284.
   PubMed Web of Science ®Google Scholar
• Liu PY, Li YH, Tsai WC, et al. Prognostic value and the changes of plasma levels of secretory type II phospholipase A2 in patients with coronary artery disease undergoing percutaneous coronary intervention. Eur Heart J. 2003;24(20):1824–1832.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Morrow DA, O’Donoghue M, et al. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol. 2007;27(11):2463–2469.
   PubMed Web of Science ®Google Scholar
• Mallat Z, Steg PG, Benessiano J, et al. Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. J Am Coll Cardiol. 2005;46(7):1249–1257.
   Web of Science ®Google Scholar
• Koenig W, Vossen CY, Mallat Z, Brenner H, Benessiano J, Rothenbacher D. Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease. Eur Heart J. 2009;30(22):2742–2748.
   Web of Science ®Google Scholar
• Kugiyama K, Ota Y, Sugiyama S, et al. Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris. Am J Cardiol. 2000;86(7):718–722.
   PubMed Web of Science ®Google Scholar
• Lind L, Simon T, Johansson L, et al. Circulating levels of secretory- and lipoprotein-associated phospholipase A2 activities: relation to atherosclerotic plaques and future all-cause mortality. Eur Heart J. 2012;33(23):2946–2954.
   Web of Science ®Google Scholar
• O’Donoghue ML, Mallat Z, Morrow DA, et al. Prognostic utility of secretory phospholipase A(2) in patients with stable coronary artery disease. Clin Chem. 2011;57(9):1311–1317.
   Web of Science ®Google Scholar
• Kempf T, Eden M, Strelau J, et al. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res. 2006;98(3):351–360.
   PubMed Web of Science ®Google Scholar
• Bermúdez B, López S, Pacheco YM, et al. Influence of postprandial triglyceride-rich lipoproteins on lipid-mediated gene expression in smooth muscle cells of the human coronary artery. Cardiovasc Res. 2008;79(2):294–303.
   PubMed Web of Science ®Google Scholar
• Frank D, Kuhn C, Brors B, et al. Gene expression pattern in biomechanically stretched cardiomyocytes: evidence for a stretch-specific gene program. Hypertension. 2008;51(2):309–318.
   PubMed Web of Science ®Google Scholar
• Xu J, Kimball TR, Lorenz JN, et al. GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res. 2006;98(3):342–350.
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim KY, Jeon JH, et al. Adipocyte culture medium stimulates production of macrophage inhibitory cytokine 1 in MDA-MB-231 cells. Cancer Lett. 2008;261(2):253–262.
   Web of Science ®Google Scholar
• Ding Q, Mracek T, Gonzalez-Muniesa P, et al. Identification of macrophage inhibitory cytokine-1 in adipose tissue and its secretion as an adipokine by human adipocytes. Endocrinology. 2009;150(4):1688–1696.
   PubMed Web of Science ®Google Scholar
• Bootcov MR, Bauskin AR, Valenzuela SM, et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A. 1997;94(21):11514–11519.
   PubMed Web of Science ®Google Scholar
• Schlittenhardt D, Schober A, Strelau J, et al. Involvement of growth differentiation factor-15/macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in oxLDL-induced apoptosis of human macrophages in vitro and in arteriosclerotic lesions. Cell Tissue Res. 2004;318(2):325–333.
   PubMed Web of Science ®Google Scholar
• Kempf T, Zarbock A, Widera C, et al. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med. 2011;17(5):581–588.
   PubMed Web of Science ®Google Scholar
• Kempf T, Björklund E, Olofsson S, et al. Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction. Eur Heart J. 2007;28(23):2858–2865.
   PubMed Web of Science ®Google Scholar
• Khan SQ, Ng K, Dhillon O, et al. Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction. Eur Heart J. 2009;30(9):1057–1065.
   PubMed Web of Science ®Google Scholar
• Wollert KC, Kempf T, Peter T, et al. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation. 2007;115(8):962–971.
   PubMed Web of Science ®Google Scholar
• Kempf T, von Haehling S, Peter T, et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol. 2007;50(11):1054–1060.
   PubMed Web of Science ®Google Scholar
• Wollert KC, Kempf T, Lagerqvist B, et al. Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non ST-elevation acute coronary syndrome. Circulation. 2007;116(14):1540–1548.
   PubMed Web of Science ®Google Scholar
• Damman P, Kempf T, Windhausen F, et al; ICTUS investigators. Growth-differentiation factor 15 for long-term prognostication in patients with non-ST-elevation acute coronary syndrome: An Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) substudy. Int J Cardiol. 2014;172(2):356–363.
   Web of Science ®Google Scholar
• Kempf T, Sinning JM, Quint A, et al. Growth-differentiation factor-15 for risk stratification in patients with stable and unstable coronary heart disease: results from the AtheroGene study. Circ Cardiovasc Genet. 2009;2(3):286–292.
   Google Scholar
• Schaub N, Reichlin T, Twerenbold R, et al. Growth differentiation factor-15 in the early diagnosis and risk stratification of patients with acute chest pain. Clin Chem. 2012;58(2):441–449.
   Web of Science ®Google Scholar
• Rohatgi, A. Usefulness of Growth Differentiation Factor-15 (GDF-15) As A Marker for Patients with Possible MI and For Predicting Coronary Disease in Asymptomatic Patients. Cardiac Biomarkers (2012) http://biomarkers.cardiosource.org/Hot-Topics/2012/02/Using-GDF-15-as-a-Marker-for-Predicting-Coronary-Disease.aspx. Accessed March 20, 2014.
   Google Scholar